Dissolution Method Development for Regulatory Approval: A Comprehensive Review and Case Study

被引:1
|
作者
Parshuramkar, Pramod [1 ]
Khobragade, Deepak [2 ]
Kashyap, Pranita [3 ]
机构
[1] Centaur Pharmaceut Pvt Ltd, Pune, India
[2] Datta Meghe Inst Med Sci, Wardha, Maharashtra, India
[3] Dr RG Bhoyar Inst Pharmaceut Educ & Res, Wardha, Maharashtra, India
来源
DISSOLUTION TECHNOLOGIES | 2023年 / 30卷 / 03期
关键词
Dissolution method development; dissolution specification; discriminatory power; dissolution apparatus; dissolution medium;
D O I
10.14227/DT300323P162
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In vitro dissolution testing is an important tool for any oral drug product. It is useful for product development and to ensure the in vivo performance of drug products throughout their commercial life without conducting clinical or bioequivalence studies after regulatory approval. It also plays a role in maintaining batch-to-batch consistency, providing quality assurance, supporting biowaiver and post-approval changes, etc. Guidelines from regulatory agencies provide expectations about the dissolution method and acceptance criteria; however, pharmaceutical manufacturers may fail to comply with the requirements or the expectations of the agencies, resulting in dissolution deficiencies. Furthermore, updates in dissolution testing may not be effectively communicated to non-industry scientists who are involved in dissolution or drug delivery research. This article provides a comprehensive review of the current American and European regulatory guidance for solid oral dosage forms followed by a case study to demonstrate how a dissolution method should be developed, which can be used as a framework for any drug product.
引用
收藏
页码:162 / 175
页数:14
相关论文
共 50 条
  • [31] Regulatory approval of used fuel dry storage facilities in Canada - An Ontario Power Generation case study
    Khan, A
    King, F
    STORAGE OF SPENT FUEL FROM POWER REACTORS, 2003, 20 : 240 - 249
  • [32] Regulatory dendritic cells in autoimmunity: A comprehensive review
    Liu, Juan
    Cao, Xuetao
    JOURNAL OF AUTOIMMUNITY, 2015, 63 : 1 - 12
  • [33] Japanese contributions to oncology drug development and regulatory approval around the world
    Fujiwara, Yasuhiro
    Nonaka, Takahiro
    CANCER SCIENCE, 2021, 112 : 954 - 954
  • [34] Clinical Development and Regulatory Approval of Acute Heart Failure Drugs in Japan
    Shinagawa, Kaori
    CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 107 - 109
  • [35] NASH: regulatory considerations for clinical drug development and US FDA approval
    Harvey, Brian E.
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (05) : 1210 - 1214
  • [36] Multidimensional Challenges in Clinical Drug Development, Regulatory Approval, and Marketing Reply
    Cortes, Javier
    Llombart-Cussac, Antonio
    Calvo, Emiliano
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (09) : 1253 - 1254
  • [37] Regulatory Considerations on the Development, Evaluation, and Approval of Therapies in Rheumatoid Arthritis Prevention
    Richard, Claudia
    Hedrick, Joseph A.
    CLINICAL THERAPEUTICS, 2019, 41 (07) : 1397 - 1400
  • [38] Development of Spectrophotometric Method for Dissolution and In Vitro Kinetic Study of Glimepiride Tablets
    Naz, Asia
    Ali, Huma
    Zafar, Farya
    Shah, Shabana N.
    Sharif, Huma
    Siddiqui, Shehla
    Zeb-un-Nisa
    Naqvi, Ghazala R.
    LATIN AMERICAN JOURNAL OF PHARMACY, 2014, 33 (09): : 1418 - 1424
  • [39] Regulatory approval of new medical devices: cross sectional study
    Marcus, Hani J.
    Payne, Christopher J.
    Hughes-Hallett, Archie
    Marcus, Adam P.
    Yang, Guang-Zhong
    Darzi, Ara
    Nandi, Dipankar
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 353
  • [40] Dissolution Method for Milnacipran Hydrochloride Capsules: Development, Validation, and Study of Changes in Dissolution Rate after Storage
    Dias, Carolina Lupi
    Rossi, Rochele Cassanta
    Bajerski, Lisiane
    Froeehlich, Pedro Eduardo
    DISSOLUTION TECHNOLOGIES, 2011, 18 (03): : 47 - 53